Biomea Fusion, Inc.
- Last sale
- Nov 12, 2026 · -6.88%
- Market cap
- $41.03M
- 72.68M shares
- Filings
- 292
Q3 2022
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2025derivedN/M FY24 yoy
Q3 2026N/M FY25 yoy
Q3 2026−4.2% FY25 yoy
- $41.03M
- —
- —
- 5.4×
- —
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Net Interest Income
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,858,000 | reported | |
| FY 2024 | 2024-12-31 | $5,644,000 | reported | |
| FY 2023 | 2023-12-31 | $8,880,000 | reported |
Pharmaceutical preparations
Biomea Fusion, Inc. is the 346th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ELTXElicio Therapeutics, Inc.———$44.4MDWTXDogwood Therapeutics, Inc.———$42.1MCNTBConnect Biopharma Holdings Ltd$64.0K99.8%86,687.5%$42.0MIBOImpact Biomedical Inc.$32.0K—36,993.8%$41.5M
BMEABiomea Fusion, Inc. (this company)———$41.0M
BHSTBioharvest Sciences Inc.$34.5M37.0%32.3%$39.7MSKYESkye Bioscience, Inc.———$39.3MGRCEGrace Therapeutics, Inc.———$38.0MATHEAlterity Therapeutics Ltd———$37.9MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Biomea Fusion, Inc. · CIK 1840439 · Engraved from SEC EDGAR